MktsMarkets

Acurx Pharmaceuticals, Inc.
NASDAQ: ACXPKey statistics
ACXP News
Stories mentioning ACXP from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 341.00 | 282.00 | 430.00 | 524.00 | 599.00 | 825.00 | 1,198 | 1,826 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 1,716 | 1,617 | 2,029 | 2,270 | 2,176 | 2,795 | 2,827 | 4,123 |
| Operating Income (Loss) | (1,716) | (1,617) | (2,029) | (2,270) | (2,176) | (2,827) | (4,123) | |
| Interest Income | 35.00 | 39.00 | 36.00 | 23.00 | 27.00 | 5.00 | 1.00 | |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (1,681) | (1,579) | (1,993) | (2,246) | (2,149) | (2,781) | (2,822) | (4,122) |
| Earnings Per Share (Basic) | (0.62) | (1.05) | (1.23) | (1.89) | (2.15) | (3.44) | (3.45) | (5.21) |
| Earnings Per Share (Diluted) | (0.62) | (1.05) | (1.23) | (1.89) | (2.15) | (3.44) | (3.45) | (5.21) |
| Weighted Average Shares Outstanding (Basic) | 2,718 | 1,499 | 1,626 | 1,190 | 1,002 | 808.00 | 818.00 | 791.00 |
| Weighted Average Shares Outstanding (Diluted) | 2,718 | 1,499 | 1,626 | 1,190 | 1,002 | 808.00 | 818.00 | 791.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ACXP
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a stock listed on the Nasdaq Stock Market under the ticker symbol ACXP. It last traded at $0.9900 (Nov 17, 2026, 4:00 PM ET), up 5.9% on the day. That gives Acurx Pharmaceuticals a market capitalisation of $6.0M.
Over the past 52 weeks ACXP has traded between $0.9000 and $7.54.
For the quarter ended Mar 31, 2026 it reported a net loss of $1.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$1.7M |
| Dec 31, 2025 | — | -$1.6M |
| Sep 30, 2025 | — | -$2.0M |
| Jun 30, 2025 | — | -$2.2M |
From Acurx Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…